Supernus Pharmaceuticals, Inc.
HealthcareNASDAQ:SUPN · NASDAQ Global Market
-$1.14 today
Vol 0.82M · Avg 0.63M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$776.8M of revenue converted into -$29.0M of net income for the selected period. Gross margin is 89.5% and net margin is -3.2%, showing how much revenue survives after costs and taxes. EPS is $-0.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M +8.6% | $661.8M +8.9% | $607.5M -8.9% | $667.2M +15.1% | $579.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $74.6M -4.3% | $77.9M -7.0% | $83.8M -3.9% | $87.2M +16.2% | $75.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $644.4M +10.4% | $583.9M +11.5% | $523.7M -9.7% | $580.0M +14.9% | $504.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 89.6% +1.4pp | 88.2% +2.0pp | 86.2% -0.7pp | 86.9% -0.1pp | 87.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $106.2M -2.4% | $108.8M +18.8% | $91.6M +22.9% | $74.6M -17.6% | $90.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $485.6M +44.6% | $335.8M -0.2% | $336.4M -10.8% | $377.2M +23.8% | $304.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $681.3M +35.6% | $502.2M -5.1% | $529.0M -0.9% | $533.9M +27.5% | $418.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $91.6M +13.9% | $80.4M -5.2% | $84.9M -0.8% | $85.5M +162.4% | $32.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $42.5M -76.1% | $178.3M +98.0% | $90.0M -41.3% | $153.4M +18.7% | $129.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 5.9% -21.0pp | 26.9% +12.1pp | 14.8% -8.2pp | 23.0% +0.7pp | 22.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$36.9M -145.1% | $81.7M +1649.9% | -$5.3M -111.4% | $46.1M -46.4% | $86.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -5.1% -17.5pp | 12.3% +13.2pp | -0.9% -7.8pp | 6.9% -7.9pp | 14.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $13.3M -18.2% | $16.2M +55.0% | $10.5M -51.8% | $21.7M +105.2% | $10.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $2.4M -65.8% | $7.1M -69.8% | $23.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$12.2M -175.1% | $16.2M +101.6% | $8.0M -45.0% | $14.6M +213.7% | -$12.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$49.0M -150.1% | $97.9M +3434.5% | $2.8M -95.4% | $60.7M -17.0% | $73.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -6.8% -21.6pp | 14.8% +14.3pp | 0.5% -8.6pp | 9.1% -3.5pp | 12.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$10.5M -143.7% | $24.0M +1552.1% | $1.5M +4440.6% | $32.0K -99.8% | $19.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$38.5M -152.2% | $73.9M +5512.8% | $1.3M -97.8% | $60.7M +13.6% | $53.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -5.4% -16.5pp | 11.2% +10.9pp | 0.2% -8.9pp | 9.1% -0.1pp | 9.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -150.7% | $1 +5460.2% | $0 -97.9% | $1 +11.9% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -151.5% | $1 +5469.6% | $0 -97.7% | $1 +6.1% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $56.5M +2.5% | $55.1M +1.0% | $54.5M +1.6% | $53.7M +1.1% | $53.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $56.5M +0.9% | $56.0M +0.8% | $55.5M -10.0% | $61.7M +13.5% | $54.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.80B
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.15B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.25B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.17B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
GRAIL, Inc.
NASDAQ:GRAL
$2.57B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.91B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Perrigo Company plc
NYSE:PRGO
$1.52B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SUPN generate?
Supernus Pharmaceuticals, Inc. (SUPN) reported $718.95M of revenue in fiscal 2025.
Is SUPN profitable?
Supernus Pharmaceuticals, Inc. (SUPN) reported -$38,550,000.00 of net income, with a net margin of -5.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.